Market closed
Amneal Pharmaceuticals/$AMRX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Amneal Pharmaceuticals
Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Ticker
$AMRX
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
7,850
Website
AMRX Metrics
BasicAdvanced
$2.4B
Market cap
-
P/E ratio
-$0.63
EPS
1.17
Beta
-
Dividend rate
Price and volume
Market cap
$2.4B
Beta
1.17
52-week high
$9.23
52-week low
$5.01
Average daily volume
1.2M
Financial strength
Current ratio
1.382
Quick ratio
0.758
Long term debt to equity
-6,721.021
Total debt to equity
-7,852.319
Interest coverage (TTM)
1.34%
Management effectiveness
Return on assets (TTM)
6.03%
Return on equity (TTM)
-185.77%
Valuation
Price to revenue (TTM)
0.849
Price to book
-25.79
Price to tangible book (TTM)
-1.64
Price to free cash flow (TTM)
9.932
Growth
Revenue change (TTM)
12.32%
Earnings per share change (TTM)
-1,144.53%
3-year revenue growth (CAGR)
9.05%
3-year earnings per share growth (CAGR)
90.23%
What the Analysts think about AMRX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Amneal Pharmaceuticals stock.
AMRX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AMRX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AMRX News
AllArticlesVideos
Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist
Business Wire·1 month ago
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call Transcript
Seeking Alpha·1 month ago
Amneal Reports Third Quarter 2024 Financial Results
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Amneal Pharmaceuticals stock?
Amneal Pharmaceuticals (AMRX) has a market cap of $2.4B as of December 23, 2024.
What is the P/E ratio for Amneal Pharmaceuticals stock?
The price to earnings (P/E) ratio for Amneal Pharmaceuticals (AMRX) stock is 0 as of December 23, 2024.
Does Amneal Pharmaceuticals stock pay dividends?
No, Amneal Pharmaceuticals (AMRX) stock does not pay dividends to its shareholders as of December 23, 2024.
When is the next Amneal Pharmaceuticals dividend payment date?
Amneal Pharmaceuticals (AMRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Amneal Pharmaceuticals?
Amneal Pharmaceuticals (AMRX) has a beta rating of 1.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.